Palatin presents preclinical data on PL8177 in diabetic nephropathy; Phase 2 BREAKOUT study enrolling

PALATIN TECHNOLOGIES INC

PL8177 preserved podocyte count and WT1 expression in diabetic rats vs. vehicle.
Glomerular hypertrophy trended toward reduction in PL8177-treated kidneys.
Data presented at International Podocyte Conference, May 24-26, 2023 in Philadelphia.
Phase 2 BREAKOUT study (bremelanotide) for diabetic kidney disease now enrolling (NCT05709444).
CEO cites melanocortin system potential for new inflammatory disease treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.